Background: Levofloxacin is a potent antibiotic with severe side effects due to its high doses.
Bacterial resistance may be due to frequent use of antibiotics. Biogenic gold nanoparticles conjugated
levofloxacin (Au-HSA-LvN-NPs) were developed by Human Serum Albumin (HSA) and nitrate reductasemediated
Methods: Au-HSA-LvN-NPs (size = 27.2 ± 1 nm) were readily generated with high emulsion stability
zeta potential (-13.3 mV). The developed nanoparticles were also characterized by UVvisible spectroscopy,
Transmission Electron Microscopy and Dynamic Light Scattering techniques.
Results: The optimized nanoparticles were found efficient against both Gram-positive bacteria and
Gramnegative bacteria specifically S. aureus (MIC-0.373 µg/ml), E. coli (MIC-0.149 µg/ml) and P.
aeruginosa (MIC-0.346 µg/ml) respectively.
Conclusion: The efficiency of bioconjugated levofloxacin got improved by 1.94 times, 2.89 times and
1.46 times against S. aureus, E. coli and P. aeruginosa respectively, in comparison to pure levofloxacin.